ClinicalTrials.gg
CompletedNCT06099873ZX-7101A-207Updated Feb 19, 2025

Study to Assess the Safety and Efficacy of ZX-7101A in Adolescents with Influenza

A Phase 3 interventional study of ZX-7101A and Placebo in Respiratory Viral Infection, sponsored by Nanjing Zenshine Pharmaceuticals. Completed at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The primary object of this study is evaluating the efficacy of ZX-7101A tablets versus placebo in the treatment of uncomplicated simple influenza in adolescents.

The seongdary object is evaluating the safety of ZX-7101A tablet in the treatment of uncomplicated simple influenza in adolescents.

Read the detailed description

In this study, adolescents aged 12 and \< 18 with uncomplicated influenza are selected as subjects. Typical systemic and/or respiratory influenza symptoms were required, and the time interval between the first onset of influenza symptoms and random enrollment was less than 48 hours. This study is divided into screening/treatment period (D1) and observation period (about 2 weeks). You will be eligible before starting study therapy on day 1 (D1). Participants were randomly assigned 1:1 to ZX-7101A group (dose 40 mg, administration once) or placebo group (dose 1 placebo tablet, administration once), with 180 participants planned to be included in each group, for a total of about 360 participants.

02

Conditions studied

  • Respiratory Viral Infection

Keywords

  • adolescent
  • ZX-7101A
03

In context

Lead sponsor

Nanjing Zenshine Pharmaceuticals is the lead sponsor of 16 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.≥12 to\<18 years of age at the time of randomization, males or females. 2.Patients in the screening period met the following criteria:

  1. Rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) test positive;
  2. Axillary temperature ≥ 37.5℃ at screening; If taking antipyretics, axillary temperature ≥ 37.5℃ after taking the drug (more than 4 hours).
  3. At least one of influenza -related systemic symptoms is moderate or greater in severity: a. muscle or joint pain, b. fatigue, c. headache, d. fever.
  4. At least one of the influenza-related respiratory symptoms is moderate or greater in severity: a. nasal congestion, b. sore throat, c. cough.

3.The first occurrence of influenza symptoms ≤ 48 hours from the time of patient randomization.

  1. Body temperature ≥ 37.5 ℃ (axillary temperature) or 37.5 ℃ (oral temperature) or 38.0 ℃ (rectal or tympanic membrane temperature)for the first time;
  2. Or at least one systemic or respiratory symptom may occur: a. nasal congestion, b. sore throat, c. cough, d. muscle or joint pain, e. fatigue, f. headache, g. fever.

4.Be able to comply with all the study procedures, complete the subject diary as required(The guardian is allowed to fill in if necessary).

5.The subject and his/her guardian are volunteer to participate in the study and sign the written form (ICF).

6.The subject agree to maintain abstinence or take reliable methods during the trial and persist in until 3 months after the administration of the product.

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment.(Meet any one of the following criteria) (1)Severe cases with one of the following conditions: Persistent high fever for more than 3 days, accompanied by severe cough, purulent sputum, bloody sputum, or chest pain; Fast breathing rate, difficulty breathing, cyanosis of lips; Delayed response, drowsiness, restlessness, and other mental changes or seizures; Severe vomiting, diarrhea, and dehydration symptoms; Concomitant pneumonia; Significant exacerbation of existing underlying diseases; Other clinical situations that require hospitalization. (2)Critical cases with one of the following conditions(Including but not limited to): Respiratory failure; Acute necrotizing encephalopathy; Shock; Multiple organ dysfunction; Other serious clinical situations that require monitoring and treatment.
  2. High risk population for severe cases. (Meet any one of the following criteria):

(1)Accompanied by the following basic diseases and judged by the investigators to be , such as lung diseases, liver diseases, kidney diseases, hematological system diseases, heart diseases, neurological and neuromuscular diseases that affect the ability to clear respiratory secretions, metabolic and endocrine system diseases, etc; (2)Subjects with low immune function, such as malignant tumors, organ or bone marrow transplants, infections, or those who have been taking for the past 3 months; (3)Clinical significance of correcting abnormalities in display; (QTc>440ms in male or QTc>450ms in female); (4)Subjects who require long-term use of drugs containing aspirin or salicylates : It is necessary to take medication containing aspirin or salicylate regularly every day for more than 14 days; (5) exceeds the standards. 3.Bronchitis, pneumonia, pleural effusion or interstitial disease confirmed by chest imaging [X-ray (anteroposterior or anteroposterior)/CT] and judged clinically significant by the investigator at screening.

4.Subjects who have developed acute respiratory tract infection, otitis media, and sinusitis within 2 weeks before screening.

5.Subjects with other infections requiring systemic anti-infective treatment, or blood routine examination at screening: \<13 years of age :white blood cell count (WBC) > 11.3 × 109/L(venous blood);≥13 to\<18 years of age :white blood cell count (WBC) > 11.0 × 109/L(venous blood).

6.Subjects with purulent sputum or suppurative tonsillitis. 7.Have difficulty in swallowing drugs or have a history of gastrointestinal diseases that seriously affect drug absorption.

8.Suspected allergic to active ingredients or of the product.

9.Body weight \< 20 kg. 10.Medications against influenza virus within 7 days before screening. 11.Have received or attenuated live vaccines within 14 days before randomization, influenza vaccines within 6 months before randomization.

12.Suspected or confirmed a history of alcohol or drug abuse.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    ZX-7101A

    Before starting study treatment on day 1 (D1), eligible subjects were randomly assigned in a 1:1 ratio to receive either ZX-7101A (1 tablet,specification:40mg, single dose) or placebo (1 tablet, single dose). A total of 360 subjects were planned to be enrolled in this study,in ZX-7101A group was planned to enroll about 180 subjects.

    Drug: ZX-7101A

  • Placebo comparator
    Placebo group

    Before starting study treatment on day 1 (D1), eligible subjects were randomly assigned in a 1:1 ratio to receive either ZX-7101A (1 tablet,specification:40mg, single dose) or placebo (1 tablet, single dose). A total of 360 subjects were planned to be enrolled in this study,in placebo group was planned to enroll about 180 subjects.

    Drug: Placebo

Interventions

  • Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water

  • DrugPlacebo

    Day1 Take one tablet of Placebo orally once with appropriate amount of warm water

06

What researchers measure

Primary outcomes

  1. The time to the remission of all influenza symptoms (hours)

    Defined as the time from the start of study treatment to the time all flu symptoms are relieved. Symptom relief was defined as all seven influenza symptoms assessed by the subject on the subject diary card(Stuffy nose, sore throat, cough, muscle or joint pain, fatigue, headache, fever or chills/sweating) were 0 (asymptomatic) or 1 (mild),nd the duration is at least 21.5 hours (approximately 24 hours -10%)

    Time frame: From accepting ZX-7101A until the 15 days after the first dosing

Secondary outcomes

  1. The time influenza RNA turns negative

    Defined as the time from initiation of treatment until the first influenza viral RNA falls below the lower limit of quantification (measured by RT-PCR)

    Time frame: From accepting ZX-7101A until the 15 days after the first dosing

  2. The time Virus Titer turns negative

    Defined as the time from initiation of treatment until the first viral titer falls below the lower limit of quantification

    Time frame: From accepting ZX-7101A until the 15 days after the first dosing

  3. Percentage of subjects with RT-PCR positive influenza virus RNA and measurable virus titer at each visit (unit: %)

    the number of subjects with RT-PCR positive influenza virus RNA and measurable virus titer /The number of subjects

    Time frame: From accepting ZX-7101A until the 15 days after the first dosing

  4. Time (in hours) for relief of 4 systemic symptoms (muscle or joint pain, weakness, headache, fever, or chills/sweating)

    Symptom remission is defined as a score of 0 (asymptomatic) or 1 (mild) for all four of the above symptoms. The duration is at least 21.5 hours (About 24 hours -10%)

    Time frame: From accepting ZX-7101A until the 15 days after the first dosing

07

Study locations

1 site
  • Fudan University affiliated Huashan Hospital
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No — The results of the trial will be used for New Drug Application.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Feb 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 25, 2023
StartActual
Nov 30, 2023
Primary completionActual
Feb 13, 2025
CompletionActual
Feb 13, 2025
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06099873
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Nov 30, 2023
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Last update
Feb 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebaloxavir marboxil

Start the discussion